GTBP
GT Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.69
−4.84%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +46.7%
- EBIT
- -51.1%
- EPS
- —
- Free cash flow
- -38.4%
- Operating cash flow
- -38.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +97.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +13.5%
- Net income
- —
- EPS
- +9.9%
- Free cash flow
- -0.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026